Prunetin

Prunetin is an isoflavone compound primarily found in red clover and kudzu that demonstrates anticancer properties through multiple cellular pathways. Research shows it may inhibit gastric and bladder cancer cell growth while suppressing inflammatory responses via NF-κB pathway modulation.

Origin & History

Prunetin (5,7-dihydroxy-4'-methoxyisoflavone) is an O-methylated isoflavone naturally occurring in leguminous plants, primarily sourced from Lablab purpureus (hyacinth bean), Glycine max (soybean), and Prunus species like black cherry bark. It is extracted using solvent-based methods (ethanol or methanol) from plant roots, leaves, or bark, followed by chromatographic purification (PMID: 36098409).

Historical & Cultural Context

No specific traditional uses for isolated prunetin were identified. The compound occurs in plants used in Ayurvedic and traditional Chinese medicine for anti-inflammatory and women's health purposes, but these uses are attributed to whole plants rather than prunetin specifically (PMID: 36098409).

Health Benefits

• May inhibit gastric cancer cell growth through necroptosis mechanisms (preliminary evidence from in vitro studies only; PMID: 32708333)
• Shows potential anti-inflammatory effects via NF-κB suppression (preclinical evidence; PMID: 23597450)
• May induce cancer cell death in urinary bladder cancer through iNOS inhibition (in vitro evidence only; PMID: 34599704)
• Demonstrates antioxidant activity through modulation of oxidative stress pathways (preclinical reviews; PMID: 40029540)
• Shows favorable safety profile with low cytotoxicity in normal cells (in vitro ADMET analysis; PMC7408406)

How It Works

Prunetin exerts its anticancer effects through induction of necroptosis, a form of programmed cell death, particularly in gastric cancer cells. The compound suppresses inflammatory responses by inhibiting the NF-κB signaling pathway, reducing production of pro-inflammatory cytokines. Additionally, prunetin may modulate estrogen receptor activity due to its isoflavone structure, though specific receptor binding affinities require further characterization.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses have been conducted on prunetin. All evidence is limited to preclinical in vitro studies on cancer cell lines, including AGS gastric cancer cells showing dose-dependent growth inhibition at 20-80 μM (PMID: 32708333, PMC7408406), and transcriptomic analyses revealing 1,118 differentially expressed genes (PMID: 35831348).

Clinical Summary

Current evidence for prunetin is limited to preclinical in vitro studies examining its effects on cancer cell lines. Research has demonstrated growth inhibition in gastric cancer cells through necroptosis mechanisms, with one study (PMID: 32708333) showing significant cell death induction. Anti-inflammatory effects have been observed in laboratory models through NF-κB suppression (PMID: 23597450). No human clinical trials have been conducted to establish therapeutic efficacy, safety profiles, or optimal dosing regimens in humans.

Nutritional Profile

Prunetin (4'-methoxy-5-hydroxyflavone; C₁₆H₁₂O₅; MW 284.26 g/mol) is an O-methylated isoflavone, not a food or macronutrient source. It is a bioactive phytochemical found in trace amounts in certain plant tissues. Key details: • Classification: Isoflavone (subclass of flavonoids); structurally the 4'-methyl ether of genistein. • Natural sources: Found in small concentrations in prunus species (e.g., cherry, plum), licorice root (Glycyrrhiza glabra), wild indigo (Baptisia australis), and some leguminous plants. Concentrations in natural sources are typically very low (micrograms per gram of dry plant material; exact amounts vary by species and tissue). • Bioactive compound profile: Functions primarily as a phytoestrogen with weak estrogenic activity due to structural similarity to 17β-estradiol; also exhibits antioxidant capacity via phenolic hydroxyl group at C-5 position (the 4'-methoxy group modestly reduces radical scavenging potency compared to unmethylated analogs like genistein). • Bioavailability notes: Like most isoflavones, prunetin is expected to have limited oral bioavailability due to extensive phase II metabolism (glucuronidation and sulfation) in the intestinal wall and liver. Gut microbiota may further metabolize prunetin, potentially generating bioactive or inactive metabolites. The 4'-methoxy group may slightly alter metabolic fate compared to genistein. Lipophilicity (LogP ~2.3) suggests moderate membrane permeability. No established dietary reference intake, recommended daily allowance, or tolerable upper intake level exists. • Macronutrients: Not applicable — prunetin is a single phytochemical compound, not a food, and contributes negligible calories, protein, fat, carbohydrate, or fiber. • Vitamins and minerals: None inherent to the compound itself. • Solubility: Poorly water-soluble; soluble in DMSO, ethanol, and other organic solvents, which impacts formulation and bioavailability in experimental and potential therapeutic contexts.

Preparation & Dosage

No clinically studied dosages exist due to lack of human trials. In vitro studies used concentrations of 10-100 μM (20, 40, 80 μM for 24-72 hours). No data on extract, powder, or standardized forms for human consumption. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Genistein, Daidzein, Resveratrol, Quercetin, EGCG

Safety & Interactions

Safety data for prunetin supplementation in humans is currently unavailable due to lack of clinical trials. As an isoflavone compound, prunetin may theoretically interact with hormone-sensitive conditions or medications affecting estrogen metabolism. Potential interactions with anticoagulant medications cannot be ruled out, as some isoflavones affect blood clotting. Pregnant and breastfeeding women should avoid prunetin supplements due to insufficient safety data and potential hormonal effects.